130 related articles for article (PubMed ID: 37975535)
1. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D
Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535
[TBL] [Abstract][Full Text] [Related]
2. Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia.
Burgess M; Keane C; Tobin JW; Law SC; Griffin A; Gill D; Ewing AD; Atkinson V; Mollee P; Sabdia MB; Saunders NA; Gandhi MK
Acta Haematol; 2023; 146(2):166-171. PubMed ID: 36273464
[TBL] [Abstract][Full Text] [Related]
3. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
4. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.
Chorti E; Kowall B; Hassel JC; Schilling B; Sachse M; Gutzmer R; Loquai C; Kähler KC; Hüsing A; Gilde C; Thielmann CM; Zaremba-Montenari A; Placke JM; Gratsias E; Martaki A; Roesch A; Ugurel S; Schadendorf D; Livingstone E; Stang A; Zimmer L
Eur J Cancer; 2024 Mar; 200():113536. PubMed ID: 38306840
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
7. ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade.
Ralser DJ; Herr E; de Vos L; Kulcsár Z; Zarbl R; Klümper N; Gielen GH; Maas AP; Hoffmann F; Dietrich J; Kuster P; Mustea A; Glodde N; Kristiansen G; Strieth S; Landsberg J; Dietrich D
Biomark Res; 2023 Jun; 11(1):56. PubMed ID: 37259155
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Cass SH; Tobin JWD; Seo YD; Gener-Ricos G; Keung EZ; Burton EM; Davies MA; McQuade JL; Lazar AJ; Mason R; Millward M; Sandhu S; Khoo C; Warburton L; Guerra V; Haydon A; Dearden H; Menzies AM; Carlino MS; Smith JL; Mollee P; Burgess M; Mapp S; Keane C; Atkinson V; Parikh SA; Markovic SN; Ding W; Call TG; Hampel PJ; Long GV; Wargo JA; Ferrajoli A
Ann Oncol; 2023 Sep; 34(9):796-805. PubMed ID: 37414216
[TBL] [Abstract][Full Text] [Related]
9. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
10. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract][Full Text] [Related]
11. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
12. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy.
Gong X; Karchin R
Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470
[TBL] [Abstract][Full Text] [Related]
13. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
14. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma.
Placke JM; Soun C; Bottek J; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Pfeiffer C; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Zimmer L; Livingstone E; Becker JC; Lodde G; Sucker A; Griewank K; Horn S; Hadaschik E; Roesch A; Schadendorf D; Engel DR; Ugurel S
Front Oncol; 2021; 11():741993. PubMed ID: 34621681
[TBL] [Abstract][Full Text] [Related]
15. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
16. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
Hoffmann F; Niebel D; Aymans P; Ferring-Schmitt S; Dietrich D; Landsberg J
Clin Epigenetics; 2020 Feb; 12(1):24. PubMed ID: 32041674
[TBL] [Abstract][Full Text] [Related]
17. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
18. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
Smithy JW; Pianko MJ; Maher C; Postow MA; Shoushtari AN; Momtaz P; Chapman PB; Wolchok JD; Park JH; Callahan MK
J Immunother; 2021 Jan; 44(1):9-15. PubMed ID: 33290361
[TBL] [Abstract][Full Text] [Related]
20. Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade.
Chen S; McMiller TL; Soni A; Succaria F; Sidhom JW; Cappelli LC; Casciola-Rosen LA; Morales IR; Sankaran P; Berger AE; Deutsch JS; Zhu QC; Anders RA; Hooper JE; Pardoll DM; Lipson EJ; Taube JM; Topalian SL
J Transl Med; 2024 Mar; 22(1):241. PubMed ID: 38443917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
